Haematology Journal Articles and Videos
Advancing Our Clinical Perspectives in Haematology – What is Your Approach?
European Oncology & Haematology, 2016;12(Suppl 1):i–viii
Optimising the Use of Ruxolitinib in Inadequately Controlled Polycythaemia Vera
European Oncology & Haematology, 2016;12(2):81–6 DOI: https://doi.org/10.17925/EOH.2016.12.02.81
Prevention of Chronic Graft-versus-host Disease and the Unique Role of Anti-human T-lymphocyte Immune Globulin
European Oncology & Haematology, 2016;12(2):93–5 DOI: https://doi.org/10.17925/EOH.2016.12.02.93
Investigating Rare Haematological Disorders – A Celebration of 10 Years of the Sherlock Holmes Symposia
European Oncology & Haematology,2016;12(1):55–61 DOI: http://doi.org/10.17925/EOH.2016.12.01.55
Professor of Hematology and head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France).
Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK.
Professor Mohty is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma.
Professor Mohty is currently president of the European Society for Blood and Marrow Transplantation (EBMT). He serves on the board of the EBMT, and the “Intergroupe Francophone du Myelome” (IFM). He is a member of the American Society of Hematology, American Society for Clinical Oncology, American Society for Blood and Marrow Transplantation, European Hematology Association, International Society for Experimental Hematology, and EBMT.
Professor Mohty has published more than 430 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals. He also serves as Editor-in-Chief of the journal Bone Marrow Transplantation, as Associate Editor for Leukemia, European Journal of Haematology and Blood Cancer Journal, as member of the editorial board of Haematologica, and as a regular reviewer in different immunology, hematology, and cancer journals such as Blood, The Lancet, and Nature Reviews.
Professor (Emeritus), Department of Hematology, The Edith Wolfson Medical Center, Holon, Israel
Prof. Eliezer Rachmilewitz received all his medical education in Israel and was the Head of the Hematology department in Hadassah Hospital in Jerusalem for 20 years. From 2000 to 2012, he was the Head of the Hematology department in Wolfson Hospital in Holon. He is continuing to work as a consultant in Wolfson Hospital and in Assuta Medical Center. He is also an adjunct professor of Medicine in New York Cornell University Presbyterian Hospital. In 2013, he was appointed as the head of medical policy division in the Israeli Medical Association.
Prof Rachmilewitz’s main area of research evolves around the pathophysiology of thalassemia. He and his colleagues described for the first time the presence of non-transferrin bound iron (NTBI) in thalassemia which is recognized as a catalyst in the formation of oxygen free radicals and generating increased oxidative stress. He initiated the first study that showed low hepcidin levels in thalassemic mice that explained their increased iron absorption. In September 2005 he published a progress report on thalassemia in the New England Journal of Medicine, and recently on “How I Treat Thalassemia” in Blood. Another area that he was one of the first to explore is Hypercoagulable State in Hemoglobinopathies. His first review on this topic was published in Blood together with his late colleague Dr. Amiram Eldor in 2002. Recently, he has been involved in the study of multiple asymptomatic ischemic lesions in the brain of patients with thalassemia.
As an extension of studies in thalassemia, he recently became interested in the role of oxidative stress in congenital and acquired hemolytic anemias and particularly in iron overload in Myelodysplastic Syndrome (MDS), which is a relatively new area. One of his recent reviews on the impact of iron overload in low risk myelodysplastic syndrome was published in Blood. Consequently, he is studying how the potential risks of oxidative damage on transformation to Leukemia and whether it can be prevented by iron chelators and/or antioxidants. One of his most recent studies is to measure iron deposition by T2* MRI in patients undergoing dialysis who receive a lot of iron, which is deposited in major organs. A review on this subject has appeared in Nephrology, Dialysis and Transplantation.
Guest professor and senior consultant at the Center for Thrombosis and Hemostasis at the University Medical Center, Mainz, Germany.
Bernhard Lämmle, M.D., was Professor of Hematology and Director of the Department of Hematology and the Central Hematology Laboratory at the University Hospital of Bern, Switzerland, from 1989 until his retirement in July 2013. He then became a guest professor and senior consultant at the Center for Thrombosis and Hemostasis at the University Medical Center, Mainz, Germany. His scientific interest concerns various clinical and laboratory aspects of hematology, hemostasis and thrombosis with a special focus on thrombotic thrombocytopenic purpura and the metalloprotease ADAMTS13. Bernhard Lämmle has coauthored more than 270 publications and held many educational and state-of-the-art lectures at international congresses.